My Girlfriend and I Have Finally Figured Out Why We Have Long Dry Spells. We’re Both Avoiding the Same Dreadful Thing.

After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

Here’s everything you need to know about the latest Google Gemini 2.0 update, including new AI models like Flash, Pro, and ...

Conestoga Capital Advisors, an asset management company, released its fourth-quarter 2024 investor letter. A copy of the ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q4 CY2024 results , with sales up 15.7% year on year to $2.91 ...

Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids ...

A groundbreaking sickle cell disease treatment has been approved for use in the UK's National Health Service (NHS). The treatment offers patients with severe forms of the condition hope for a ...

Keep your eye on the ball” is a motto for many athletes—and for astronomers trying to find Earth-threatening space rocks ...

Journave, the first non-addictive opioid-like pain medication, was developed based on Yale research from the ’90s.

Despite new medication, cystic fibrosis often leads to permanent lung damage. Working with an international team, researchers from the Technical University of Munich (TUM) have discovered that the ...

Announced in December, 2.0 Flash Thinking rivals OpenAI's o1 and o3-mini reasoning models in that it's capable of working ...

As shares of Boston-based Vertex shot higher on the news of its non-opioid pill, Journavx, we took a look at investment in startups focused on pain management and treatment. Turns out there’s quite a ...